PDT, a new therapeutic procedure for the management of many malignant conditions including skin cancer, involves the administration of a photosensitizing compound followed by illumination of the lesion with visible light. We earlier showed an involvement of: (i) WAF1/ p21-cyclins (D1 and E)-cdk (2 and 6) network; and (ii) Rb/E2F-DP machinery during silicon phthalocyanine (Pc4)-PDT-mediated cell cycle dysregulation and apoptosis of human epidermoid carcinoma (A431) cells. Here, we investigated the involvement of EGFR-pathway during antiproliferative responses of Pc4-PDT in A431 cells and during ablation of murine skin papillomas. Pc4-PDT of A431 cells was found to result in a timedependent down-modulation of the protein expression and phosphorylation of EGFR and Shc (an immediate downstream molecule in EGFR-pathway), during progressive increase in apoptotic response. To establish the relevance of these in vitro ®ndings to in vivo situations, we subjected chemically-as well as ultraviolet B radiation-induced squamous papillomas in SENCAR and SKH-1 hairless mice, respectively, to Pc4-PDT, and assessed its eect on EGFR-pathway during ablation of these tumors. Pc4-PDT was found to result in a timedependent: (i) inhibition of protein expressions of EGFR; and (ii) tyrosine phosphorylation of EGFR and Shc; and (iii) induction of apoptosis, during the regression of these tumors. These data suggest the involvement of EGFRpathway during the antiproliferative eects of PDT. It is tempting to speculate that inhibitors of EGFR could enhance the therapeutic ecacy of PDT. Oncogene (2001) 20, 2314 ± 2317.
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Keywords: PDT; EGFR; Shc; cell cycle; apoptosis Photodynamic therapy (PDT), relatively a new therapeutic procedure, is used for the management of a variety of solid tumors including skin cancer, and is showing promise for the treatment of many nonmalignant diseases including many dermatological disorders (Dougherty et al., 1998; Oleinick and Evans, 1998; Kalka et al., 2000b) . PDT involves a selective uptake of a porphyrin based photosensitizing chemical in the tumor relative to the surrounding normal tissue followed by irradiation of the tumor with visible or near infrared light that is typically derived through a laser (Dougherty et al., 1998; Oleinick and Evans, 1998; Kalka et al., 2000b) . This causes a photoactivation leading to an oxidative damage to a variety of cellular targets that subsequently results in the death of cancerous cells and thereby ablation of the tumor. The mechanism(s) of the PDT-mediated cell killing is not fully understood.
Many studies have shown that PDT is associated with apoptotic death of cancer cells in vitro and in vivo (Dougherty et al., 1998; Oleinick and Evans, 1998; Kalka et al., 2000b) . Studies from this laboratory have shown the involvement of apoptosis as an early event in ablation of: (i) RIF-1 implanted tumors in C3H mice (Zaidi et al., 1993) ; (ii) ovarian cancer (OVCAR-3) tumor xenografts (Colussi et al., 1999) and SW480 human colon cancer xenografts in nude mice (Whitacre et al., 2000) ; and (iii) chemically-induced papillomas in mouse skin, during silicon phthalocyanine (Pc4)-PDT (Agarwal et al., 1996) . We earlier showed an involvement of: (i) WAF1/p21-cyclins (D1 and E)-cdk (2 and 6) network (Ahmad et al., 1998a) ; and (ii) Rb/E2F-DP machinery (Ahmad et al., 1999) , during Pc4-PDTmediated cell cycle deregulation and apoptosis of human epidermoid carcinoma (A431) cells. Although, based on many studies, the involvement of multiple pathways during PDT-mediated cell destruction and apoptosis is becoming clear (Ahmad et al., 1998a (Ahmad et al., , 1999 Gupta et al., 1998; Kawaguchi et al., 2000; Chiu et al., 2000; Engbrecht et al., 1999; Kim et al., 1999; Zhang et al., 1999; Assefa et al., 1999; Varnes et al., 1999; Granville et al., 1998a,b; Tajiri et al., 1998; Kessel and Luo, 1998; He et al., 1998) , understanding of the molecular mechanism(s) involved in the PDTmediated cell cycle deregulation and apoptosis is far from complete. A proper understanding of these pathways may lead to development of strategies for improving treatment protocols and, therefore, therapeutic ecacy of PDT.
In this study, employing in vitro (human squamous carcinoma A431 cells) and in vivo (chemically-and ultraviolet B radiation-induced skin tumors in SEN-CAR and SKH-1 hairless mice respectively) models, we investigated our hypothesis that EGFR tyrosine kinase-pathway is an important contributor of the antiproliferative response of PDT that includes cell cycle dysregulation and apoptosis. The rationale for this hypothesis is based on three major observations. Firstly, based on many studies (Ahmad et al., 2000 and references therein) , it is becoming clear that multiple pathways are involved during PDT-mediated apoptosis. Secondly, a recent study demonstrated that EGFR is required to maintain the proliferative population in the basal cell compartment of papillomas and in the absence of EGFR, cycling tumor cells migrate into the suprabasal compartment and initiate the dierentiation program prematurely (Hansen et al., 2000) . These changes were found to be associated with cell cycle arrest. This study clearly suggests that the EGFRpathway could be exploited for the management of skin cancer and other epidermal tumors. Finally, most human tumors, especially squamous cell carcinomas, express high levels of EGFR and this overexpression is believed to be responsible for cellular proliferation and cancer growth (Woodburn, 1999) . Further: (i) EGFR has been shown to be activated by dierent skin tumor promoters in vitro and in vivo (Ahmad et al., 1998b and references therein); (ii) inhibition of EGFR-tyrosine kinase is known to result in an apoptotic cell death and arrest in cell cycle progression in the G1 phase (Woodburn, 1999) ; and (iii) our studies have shown an induction of G1 phase arrest of cell cycle and apoptosis by PDT (Ahmad et al., 1998a) . It is also important to mention here that, in recent years, the inhibition of EGFR is being considered as an important weapon in a number of areas of cancer therapy, including proliferative, angiogenic, invasive, and metastatic aspects (Woodburn, 1999) . The model photosensitizer employed in this study was a silicon phthalocyanine compound [HOSiPcOSi(CH 3 ) 2 (CH 2 ) 3 N(CH 3 ) 2 ] termed as`Pc4' that was developed at this institution . In this study, for our in vitro experiments, we employed A431 cells, which are known to over-express EGFR inasmuch as it is regarded as a model for studying EGFR and its signal transduction (Graness et al., 2000) .
In this study, under the experimental condition employed, we ®rst evaluated the eect of PDT on apoptosis as assessed by the immunoblot analysis of PARP. As shown in Figure 1 , PDT of the cells resulted in a cleavage of PARP indicative of apoptosisinduction as early as 0.5 h post-PDT, thus con®rming our earlier observations showing that Pc4-PDT results in an induction of apoptosis in A431 cells. We then evaluated the eect of PDT on the protein expression of EGFR where the immunoblot analysis data demonstrated that PDT of A431 cells resulted in a time-dependent decrease in EGFR protein expression (Figure 1) . To assess the eect of Pc4-PDT on the tyrosine phosphorylation of EGFR, we immunoprecipitated EGFR followed by immonoblot analysis of the immunoprecipitates with an anti-phosphotyrosine antibody (PY20). As shown in Figure 1 , PDT was found to result in a time-dependent inhibition of EGFR tyrosine phosphorylation. Studies have implicated that EGFR is a 170 kDa transmembranous glycoprotein which is overexpressed in a wide variety of solid human cancers and has been recognized to play an important role not only in cellular proliferation but also in a number of processes, likely to be important for tumor progression, such as cell motility, cell adhesion, invasion, and angiogenesis (Woodburn, 1999) . Because of these properties associated with EGFR signaling pathway, in recent times, EGFR-inhibition is being regarded as an approach for the management of many solid tumors including skin cancer (Fry, 1999) .
Studies have shown that the activation of EGFR stimulates a series of downstream signaling events and the carboxy-terminal domain of EGFR, which contains tyrosine residues that are autophosphorylated upon ligand binding, plays an important role in the regulation of signal transduction pathways (Fry, 1999; Schmidt-Ullrich et al., 1997; Nakamura et al., 1996) . These phosphorylated tyrosine residues are responsible for the protein-protein interactions between the activated receptor and several cellular proteins containing Src homology 2 (SH2) domains. Thus, SH2 domain plays a critical role in signal transduction associated with cellular proliferation and transformation. Shc is an adaptor protein that contains a SH2 domain, which interacts with EGFR and following Figure 1 Eect of Pc4-PDT on PARP cleavage and protein expression and tyrosine phosphorylation of EGFR and Shc in A431 cells. The A431 cells were maintained in Dulbecco's Modi®ed Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, in an atmosphere of 95% air / 5% CO 2 in a 378C humidi®ed incubator. The water-insoluble silicon-phthalocyanine photosensitizer Pc4 [HOSiPcOSi(CH 3 ) 2 (CH 2 ) 3 N(CH 3 ) 2 ] was provided by Ying-Syi Li and Malcolm E Kenney from the Department of Chemistry, Case Western Reserve University. The formulation of Pc4 is described earlier (Kalka et al., 2000a) . The cells were subjected to Pc4-PDT (5 mM Pc 4; 20 kJ/cm 2 light, wavelength=668+2 nm) as described earlier (Ahmad et al., 1998a) , and harvested at 0.25, 0.5, 1, 3, and 6 h following the light treatment. Total cell lysates were prepared and 50 mg protein was subjected to immunoblot analysis using anti-PARP, anti-EGFR or anti-Shc antibodies obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). For tyrosine phosphorylation, the protein (50 mg) was immunoprecipitated using anti-EGFR or anti-Shc antibodies and immunoprecipitates were subjected to immunoblot analysis using an anti-phosphotyrosine antibody (PY20; Santa Cruz Biotechnology, Santa Cruz, CA, USA). The details of cell lysate preparation, immunoprecipitation and immunoblot analysis are similar as described earlier (Ahmad et al., 1998a) . Equal loading was con®rmed by stripping the membrane and re-probing it with bactin antibody obtained from Santa Cruz Biotechnology (data not shown). The data shown here is from a representative experiment repeated three times with similar results
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Modulation of EGFR pathway by photodynamic therapy N Ahmad et al tyrosine phosphorylation. Shc is also known to act as an adaptor for other SH2 containing proteins in cell signaling including those in Grb2-SOS-ras-raf pathway (Fry, 1999; Schmidt-Ullrich et al., 1997; Nakamura et al., 1996) . This ultimately results in the activation of MAPK pathway that has been implicated in cellular proliferation and apoptosis. Because of its important role in signaling events leading to cellular proliferation, we assessed the eect of PDT on modulations in Shc. As shown in Figure 1 , PDT of A431 cells resulted in a signi®cant time-dependent decrease in the protein expression as well as tyrosine phosphorylation of both 52 and 46 kDa Shc proteins. This is an important observation because studies have shown that the overexpression of Shc gene results in a malignant transformation of cells via downstream events (Fry, 1999; Schmidt-Ullrich et al., 1997; Nakamura et al., 1996) . It is also important to emphasize here that the down modulation of EGFR and Shc protein expression and its phosphorylation is an early event following PDT, occurring as early as 0.25 h post-PDT, a time when apoptosis was not evident. Therefore, this may be a cause rather than a consequence of apoptosis in our system. Further, because multiple pathways have been identi®ed to be involved in PDT-mediated cell killing and our recent studies have shown the involvement of Fas-pathway in Pc4-PDT-mediated apoptosis of A431 cells , it is clear that EGFR inhibition-mediated signaling is a partial contributor of the apoptosis by PDT.
Since PDT is best-suited for the treatment of skin cancers, our major interest was to investigate the involvement of the EGFR-pathway as a mechanism of PDT-mediated skin cancer cell destruction. Because Figure 2 Eect of Pc4-PDT on PARP cleavage, protein expression and tyrosine phosphorylation of EGFR and tyrosine phosphorylation of Shc, during the ablation of (a) chemically-induced skin papillomas in SENCAR mice, and (b) ultraviolet B radiation-induced skin papillomas in SKH-1 hairless mice. SENCAR mice (female, 6 weeks old) obtained from the National Cancer Institute (Fredrick, MD, USA) and SKH-1 hairless mice (female, 6 weeks old) obtained from Charles River Laboratories (Wilmington, MA, USA) were employed. The animals were subjected to a 12 h light/dark cycle and housed in the Animal Resource Facility of CWRU. The details of tumor protocol are described earlier (Kalka et al., 2000a) . Brie¯y, the mice were treated with a single skin application of 7,12-dimethylbenz(a)anthracene (DMBA) (12.5 nmol in 0.2 ml acetone per mouse) and 1 week later the animals were subjected to twice weekly applications of TPA (4 nmol in 0.2 ml acetone) on the skin. At 14 weeks using this protocol, the SENCAR-mice showed multiple benign squamous papillomas of 3 ± 6 mm diameter. For establishing ultraviolet B radiationinduced skin tumors, the SKH-1 mice were irradiated three times per week with UVB light (180 mJ/cm 2 ) with a bank of four Westinghouse FS-40-T-12¯uorescent sunlamps (National Biological Corp., Twinsburg, OH, USA) equipped with a UVB Spectra 305 Dosimeter (Daavlin, Bryan, OH, USA). This light source emits *80% radiation in the range of 280 ± 340 nm with peak emission at 314 nm. The sunlamps were covered with Kodacel TA401/407 triacetate ®lters, which blocks wavelength emission below 300 nm from the FS40 sunlamps. Using this protocol, the mice developed multiple squamous papillomas (2 ± 4 mm) in 3 months time. Two tumors per animal were subjected to Pc4-PDT (Pc 4=1 mg/kg body weight; 150 J/cm 2 light from an argon-pumped dye laser) and two untreated tumors in the same animal were covered with a light-impermeable tape to serve as controls. The detail of tumor experiments, formulation of Pc4 and light irradiation are similar as given in an earlier publication from this laboratory (Kalka et al., 2000a) . At speci®ed times following the irradiation with light, the mice were sacri®ced, tumors were removed and tissue lysates were prepared. Twenty-®ve mg protein was subjected to immunoblot analysis using anti-PARP antibody, anti-EGFR or anti-Shc antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA). For tyrosine phosphorylation, the protein (50 mg) was immunoprecipitated using anti-EGFR or anti-Shc antibodies and immunoprecipitates were subjected to immunoblot analysis using an anti-phosphotyrosine (PY20) antibody (Santa Cruz Biotechnology). The details of cell lysate preparation, immunoprecipitation and immunoblot analysis are similar as described earlier from this laboratory (Ahmad et al., 1998a; Kalka et al., 2000a) . Equal loading was con®rmed by stripping the membrane and re-probing it with b-actin (data not shown). The data shown here is from a representative experiment repeated four times with similar results for translation of any in vitro observation to human situations, the studies must be conducted in relevant animal models, in our in vivo studies, we selected two skin cancer animal models viz chemically-induced skin papilloma in SENCAR mice and ultraviolet B radiation-induced skin tumors in SKH-1 hairless mice. The later has much relevance to human skin cancer and is a well-employed animal model in studies related to photocarcinogenesis and UV response (Mukhtar and Elmets, 1996) . We subjected the established skin tumors in these mice to Pc4-PDT and assessed the involvement of the EGFR-pathway during apoptosis and tumor regression. The involvement of apoptosis was evident from the immunoblot analysis of PARP where PDT was found to result in a signi®cant PARP cleavage in both skin tumor models (Figure 2) . We next assessed the eect of PDT on the protein expression as well as tyrosine phosphorylation of EGFR. As shown in Figure 2 by immunoblot analysis, PDT of skin tumors, in both animal models, resulted in signi®cant downmodulation of EGFR protein expression and its tyrosine phosphorylation. We also evaluated the eect of PDT on tyrosine phosphorylation of Shc protein during tumor regression in these mouse models. As shown by the data in Figure 2 , PDT resulted in signi®cant inhibition of Shc-phosphorylation.
Taken together, our study, for the ®rst time, suggests the involvement of the EGFR-pathway as a mechanism of PDT-mediated cell destruction both under in vitro and in vivo situations. However, detailed mechanistic studies are in our future plan to investigate the eect of PDT on other down-stream events in the EGFRpathway that includes PLCg-IP3-raf-MAPK-cascade. Our study may be helpful in devising novel strategies for the treatment of skin cancer as recent studies have shown that the EGFR is required to maintain the proliferative population in the basal compartment of epidermal tumors. We suggest that pharmacological intervention with the inhibitors of the EGFR-pathway may increase the therapeutic ecacy of PDT against cancer.
